LEHI, Utah, July 24, 2025 /PRNewswire/ — Amare Global, The Mental Wellness Company™, is pleased to announce a powerful new chapter; effective immediately, David Chung, Owner and Chairman of Amare Global, will assume the role of Chief Executive Officer. With an unmatched passion for Amare’s mission and a relentless drive to see every brand partner succeed, Chung is stepping into this role to lead Brand Partners into the most exciting and expansive era in Amare history.
“We are grateful for Asma Ishaq’s leadership and wish her continued success,” said Chung of Amare’s former CEO.
Amare Global’s mission is to lead the global mental wellness movement under Chung’s visionary leadership. Chung relays, “Amare is shifting into high gear. This is a moment of alignment, acceleration, and absolute belief in our purpose, our people, and our potential. Brand Partners, now is your time. This shift will create greater stability as we invest deeper, dream bigger, and execute bolder than ever before. This is more than a leadership transition—it’s a leadership elevation.”
A serial entrepreneur, Chung has an extensive track record of building brands, developing cutting-edge innovation, and leading high-performance teams. Chung will focus on expanding innovation, driving global growth, and deepening Amare’s impact as an industry leader.
About Amare Global
Amare Global® is recognized as a category leader in the mental wellness movement, offering innovative solutions informed by the powerful relationship of the gut microbiome and the gut-brain axis (GBX). Dedicated to quality and backed by award-winning US patented formulations, Amare Global is committed to delivering transformative solutions that foster love—Amare means “to love” in Latin.
ข่าวที่เกี่ยวข้อง
- Xinhua Silk Road: Jing’an District promotes investment opportunities, global business cooperation at 2026 CIIE
- Binance Blockchain Week Bangkok 2026 Unveils First Wave of Speakers, Spotlighting the Convergence of Traditional Finance and Digital Assets
- Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity
- Ali Y. Koç: ‘The Energy Transition Has Become the Cornerstone of Competitiveness in Industry’
